 effect low-dose warfarin risk stroke patients nonrheumatic atrial fibrillation Boston Area Anticoagulation Trial Atrial Fibrillation Investigators BACKGROUND Nonrheumatic atrial fibrillation risk stroke atrial thromboemboli uncertainty efficacy risks long-term warfarin therapy stroke METHODS unblinded trial long-term low-dose warfarin therapy prothrombin-time ratio patients nonrheumatic atrial fibrillation control group warfarin aspirin RESULTS total patients trial warfarin group control group average years Prothrombin times warfarin group target range percent time percent patients warfarin drug strokes warfarin group incidence percent year strokes control group incidence percent year reduction percent risk stroke warfarin control incidence ratio percent confidence interval deaths death rate warfarin group control group percent percent year incidence ratio percent confidence interval fatal hemorrhage group frequency events hospitalization transfusion groups warfarin group rate minor hemorrhage control group patients CONCLUSIONS Long-term low-dose warfarin therapy effective stroke patients non-rheumatic atrial fibrillation safe careful monitoring